Equities Analysts Issue Forecasts for ENTA Q2 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Research analysts at HC Wainwright raised their Q2 2026 EPS estimates for Enanta Pharmaceuticals in a report released on Tuesday, February 10th. HC Wainwright analyst B. Folkes now expects that the biotechnology company will post earnings per share of ($0.51) for the quarter, up from their previous forecast of ($0.54). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.73) EPS, FY2027 earnings at ($2.53) EPS, FY2028 earnings at ($3.23) EPS, FY2029 earnings at ($2.40) EPS and FY2030 earnings at ($2.19) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. The company had revenue of $18.62 million during the quarter, compared to analysts’ expectations of $16.14 million.

ENTA has been the topic of several other research reports. JPMorgan Chase & Co. initiated coverage on Enanta Pharmaceuticals in a research report on Friday, November 14th. They set an “overweight” rating and a $17.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Enanta Pharmaceuticals Trading Up 0.8%

Enanta Pharmaceuticals stock opened at $14.25 on Thursday. The company has a fifty day simple moving average of $14.11 and a 200-day simple moving average of $11.41. The stock has a market cap of $413.54 million, a P/E ratio of -4.45 and a beta of 0.98. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $17.15.

Insiders Place Their Bets

In other news, insider Tara Lynn Kieffer sold 2,106 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $29,968.38. Following the transaction, the insider directly owned 30,620 shares in the company, valued at approximately $435,722.60. This trade represents a 6.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jay R. Luly sold 4,743 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $67,492.89. Following the completion of the sale, the chief executive officer owned 858,026 shares of the company’s stock, valued at approximately $12,209,709.98. This trade represents a 0.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 11,961 shares of company stock valued at $170,149 over the last quarter. Company insiders own 11.48% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. CWM LLC lifted its position in Enanta Pharmaceuticals by 22.1% during the 2nd quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 3,879 shares during the period. Bank of Montreal Can raised its stake in shares of Enanta Pharmaceuticals by 32.8% during the second quarter. Bank of Montreal Can now owns 33,868 shares of the biotechnology company’s stock worth $256,000 after purchasing an additional 8,365 shares during the last quarter. Strs Ohio acquired a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth $50,000. Mirae Asset Global Investments Co. Ltd. grew its position in Enanta Pharmaceuticals by 333.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 2,758 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in Enanta Pharmaceuticals in the 3rd quarter valued at $125,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.